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Abstract
Osteogenic sarcoma is the most common primary bone cancer frequently 
affecting children and teenagers. Despite many years of research, little have the 
survival rates changed in the last fifty years. Early diagnosis, a complete systemic 
treatment program with a good tumor response and adequate margins continue 
to be the main determinants of patients’ prognosis in this disease. Neoadjuvant 
chemotherapy followed by surgery and subsequent adjuvant systemic treatment 
remain the standard of care. Numerous reconstruction options available provide 
these patients better function and improved quality of life.
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1. Introduction
Osteosarcoma, also known as osteogenic sarcoma, is a primary bone malignancy 
characterized for the production of osteoid, the mineralized portion of bone matrix 
[1]. Different from what its name suggests the origin of the tumor is not bone 
itself, but mesenchymal stem cells and osteosarcomas can also be found in soft 
tissues unrelated to any bone [2]. The incidence is approximately 1000 new cases 
each year in the United States [3]. Osteosarcoma is the third most common cancer 
in adolescents and is the most frequent primary bone malignant tumor in this age 
group. The peak incidence is between the second and third decade of life, although 
there is a second peak of patients aged older than 60 years of age [4, 5]. This tumor 
can subclassified according to histologic grade, location within the bone and the 
histologic characteristics of the matrix, more than 90% are of high grade, intra-
medullary location conventional ones [6]. The most common histologic subtypes 
are osteoblastic, chondroblastic, fibroblastic and telangiectatic. Additionally, these 
tumors can be classified as primary or secondary, depending on if the origin is in 
normal bone or altered bone due to prior pathology, for example Paget’s disease, 
or radiation [7]. From a genetic perspective, osteosarcomas are characterized by 
highly disorganized genomic aberrations rather than a constant genetic alteration 
commonly found in other tumors [8]. Despite this, it has been linked to alterations 
in some specific genetic pathways expressed as syndromes. Such as Li-Fraumeni 
syndrome or Rothmund-Thomson syndrome or an alteration of the Rb protein caus-
ing retinoblastoma early in life as well as osteogenic sarcomas [9].
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2. Clinical presentation
Osteosarcomas most commonly occur in the metaphysis of long bones, for the 
most part around the knee in the distal femur (43%0 or proximal tibia (23%), fol-
lowed in frequency by the humerus (10%) (Figure 1) [10]. One in ten patients has a 
tumor of axial location, most commonly in the pelvis. Tumors of axial location tend 
to have a worse prognosis with higher recurrence rates and more advanced stages at 
presentation [10–12]. Patients complaint about intermittent pain and swelling, the 
pain is known to be severe enough to awake the patient during sleep hours [13]. Pain 
of a high intensity can potentially be an indication of an impending pathological 
fracture, fact that occurs in up to 10% of these patients [14]. A pathological fracture 
may represent a more aggressive tumor and the microRNA profile of tumors that 
fractured have been shown to be different that those without a break. Additionally, 
tumors that presented with a fracture were associated with a higher risk of meta-
static spread as well as a worse prognosis overall [14].
About 20% of osteosarcoma patients have metastatic disease at presentation. 
Most of those secondary lesions are in the lung, bone being the second most com-
mon spread location [10]. Tumor size has been implicated as a risk factor for lung 
spread [15]. When osteogenic sarcoma presents in older population, there is a 
more frequent axial location compared to younger patients, being almost 40% of 
the elderly patients versus 10% in children and teenagers [16]. Additionally, the 
older patients tend to have larger tumors, more frequency of metastatic disease at 
presentation and a worse general prognosis with less opportunity for limb salvage 
procedures and inability to receive the full systemic treatment protocol as compared 
to younger patients [17]. Moreover, when the chemotherapy response seems to 
Figure 1. 




be poorer in these patients with a lower percentage of necrosis noted on the post-
chemotherapy tumor resection piece [10]. The 5-year overall survival is 50% for the 
elderly when surgical treatment is feasible, when surgery is not an option that rate 
drops to 8% [18].
3. Staging
The assessment of osteosarcoma patients usually begins with orthogonal plain 
radiographs of the site of pain or mass. Plain films usually reveal an aggressive 
appearing lesion that prompts more advanced imaging studies such as a CT scan 
or ideally an MRI with and without contrast of the entire affected bone. On radio-
graphic imaging the lesions may be more blastic, lytic or mixed pattern depending 
on the osteosarcoma subtype. In more advanced cases, there will be cortical perme-
ation and an associated soft tissue component, although this is a more common find-
ing in Ewing’s sarcomas [19]. For purely lytic lesions, radiographic evidence is only 
present when a substantial percentage of the bone has been affected (30–50%), thus 
the recommendation in cases of persistent symptoms is to proceed with an MRI even 
with a negative plain film [20]. Additional findings on radiographs include a wide 
area of transition, cortical destruction and a periosteal reaction such as Codman’s 
triangle or a sunburnt pattern (Figure 2) [21].
The next imaging study should be a full bone length MRI with and without 
contrast of the affected area, this will serve diagnostic and staging purposes as 
well, since it has the ability of detecting skip lesions. MRI studies provide informa-
tion regarding the complete extent of the tumor within the bone, and its closeness 
to surrounding structures such as vessels and nerves. Additionally, it provides 
information regarding joint invasion, and, extremely important in the pediatric 
population, physis involvement by the tumor [22]. This information will dictate the 
proposed surgical intervention (Figure 3). After neoadjuvant chemotherapy and 
prior to the definitive surgical treatment a new MRI with and without contrast of 
the affected bone must be obtained for tumor re-assessment.
Following the initial images, usually proceeds a close or open biopsy of the 
lesion for pathology confirmation of the diagnosis and grading of the tumor. It is 
Figure 2. 
Radiographic images of a patient with a distal femur conventional, central, osteoblastic, high grade 
osteosarcoma. The tumor presents a mixed, blastic and lytic, moth-eaten pattern.
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paramount that the biopsy is performed by a surgeon specialized and with experi-
ence in bone tumors, so that it can be done following important principles inherent 
to the specialty and have those not be respected it can potentially hinder the  
possibility of a limb salvage procedure for the patient [23].
Once the diagnosis of osteosarcoma has been confirmed, the next step is to pro-
ceed with staging of the patient. Approximately, 20% of patients debut with stage 
IV cancer [24]. Osteosarcomas are known to spread most commonly to lungs, 80% 
of the metastases, followed by bones (10%) [25, 26]. Therefore, the next imaging 
studies will be directed to assess the most common sites of spread. The lung assess-
ment is performed with a non-contrasted chest CT and the bone staging can be 
performed by a bone scan or, more recently, with a PET-CT scan (Figures 4 and 5). 
Figure 3. 
MRI of the tibia of a 15-year-old patient with an osteoblastic osteosarcoma of the proximal tibia respecting the 




Patients with metastatic disease at presentation have a worse prognosis than those 
with localized disease having an overall survival at 5 years of 40% or less [27]. Bone 
metastases have a particularly worse prognosis with higher rates of local recurrences 
and an overall survival of 13% [26].
Additional studies prior to the start of treatment, will be oriented at making a 
basal assessment of organs potentially affected by chemotherapy. Consequently, 
the patient will obtain an echocardiogram, kidney function studies, hemogram and 
complete metabolic panel as well as an audiology test [13]. Additionally, patients 
should be referred for fertility counseling since the systemic treatment is known to 
decrease the chances of conceiving even many years after the finalization of chemo-
therapy. Male patients present with particularly worse chances of conceiving than 
females and the cumulative dose of the drugs used seem to be the most important 
determinant factor to predict the ability to conceive after treatment [28].
4. Treatment
Currently, the treatment of localized osteogenic sarcoma is the same, inde-
pendent of subtype and despite its different behaviors and genetic profiles, and 
includes a plan of neoadjuvant chemotherapy, followed by local treatment with 
Figure 4. 
Non-contrasted chest CT depicting peripheral lung nodules (circled) consistent with metastatic osteosarcoma.
Figure 5. 
Tecnecium-99 bone scan of a patient with a distal femur osteosarcoma. No other bone lesions were present.
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surgical resection with a subsequent round of adjuvant chemotherapy [29]. This 
plan was first implemented in the 1970’s and improved long-term survival rates 
from its original 20% to the current 70%, which has remained unchanged for the 
past five decades [30]. The three main reasons for treatment failure are local recur-
rences, distant disease spread and the development of drug resistance [31].
Systemic treatment for young patients includes two cycles of 5 weeks with high 
dose methotrexate, doxorubicin and cisplatin (MAP) [32]. Once the neoadjuvant 
cycle has finalized new imaging studies are obtained and the surgical procedure is 
planned. The resection piece is afterwards analyzed by the pathologist who must 
inform the percentage of necrosis, a key factor of prognostic significance and a 
proxy for the tumor chemotherapy response [33]. Following local treatment, 3 to 
6 cycles of the same drug regimen (MAP) are given to the patient.
Before the implementation of chemotherapy as part of the treatment plan of 
these patients, even the ones with localized disease, most patients underwent a 
limb amputation, and despite this aggressive procedure still had poor survival rates. 
Nowadays, the standard of care for most patients is a limb salvage procedure which 
has shown similar survival rates to an amputation when systemic treatment was 
added with a much-improved function and quality of life [34, 35]. The main goal of 
limb salvage procedures is to completely resect the tumor while preserving impor-
tant structures for the limb survival as well as the patient’s function. Several studies 
have addressed the importance of achieving adequate margins in a resection as a 
determinant factor for the feasibility of the limb salvage option [33, 36, 37]. Local 
recurrences, which occur in 10–15% of these patients, has been linked to the margin 
adequacy as a predicting factor [38].
Once a decision has been made regarding the limb salvage procedure, several 
options present in terms of reconstruction alternatives, all with their specific 
advantages and disadvantages. Resection and reconstruction with an endoprosthetic 
device, a non-biologic option, is the main trend worldwide currently (Figure 6). 
While the biologic alternatives include allografts, vascularized fibula, distraction 
osteogenesis or recycled and sterilized bone autograft [39–43]. The latter can be 
achieved through several different techniques such as pasteurization, irradiation, 
autoclave or most recently the use of liquid nitrogen [44].
Endoprosthetic reconstructions have shown good results in terms of function at 
short and medium-term. Among its disadvantages it is its high cost, low accessibil-
ity in some countries and limited survival (50–76% at 10 years) with a high rate of 
Figure 6. 





reoperation specially in pediatric patients, an age where primary bone malignant 
tumors are most frequent [45]. Allografts require a bone bank with matching bone 
pieces. Furthermore, allografts have the potential to transmit diseases and, in some 
cases, patient acceptance may be an added obstacle [46]. Bone transport is a lengthy 
complex treatment with multiple surgical procedures usually involved [43].
Figure 7. 
Case of a 15-year-old male with an osteoblastic osteosarcoma abutting the proximal tibial physis, treated with 
limb salvage surgery with liquid nitrogen pretreated bone tumor autograft. Careful surgical planning allowed 
the proximal physis to be preserved.
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Frozen autografts recycled in liquid nitrogen are a biologic solution with the 
advantages of low cost, easy access, complete removal of viable tumor, bone 
morphogenic protein preservation, osteoconduction and osteoinduction properties 
maintained, perfect matching at the osteotomy site, does not require a bone bank, 
allows reattachment of tendons and ligaments, no disease transmission and no graft 
rejection (Figure 7) [47]. Among its disadvantages, the bone piece cannot be sent 
for full pathology analysis and thus provide the information about the percentage of 
necrosis obtained after systemic treatment in the indicated cases. Nonetheless, the 
surrounding soft tissues which are resected prior to submerging the piece in LN are 
sent to pathology. This technique accomplishes full necrosis of the tumoral cells and 
prior studies have shown that the soft tissue resection prior to the sterilization in 
LN is representative of the tumor response to chemotherapy [48]. Additionally, this 
procedure has shown no difference in terms of bone resistance to compression when 
compared to unfrozen bone. This allows for the initial resistance of the reconstruc-
tion, being comparable or even superior to allografts [48].
One particular scenario, the treating orthopedic oncologist should be aware of is 
the case of an osteosarcoma with a pathological fracture at presentation. Fractures 
through an osteogenic sarcoma can occur in up to 10% of the cases (Figure 8) [14]. 
In the past, this circumstance used to be a contraindication for a limb salvage proce-
dure and patients were indisputably recommended for an amputation. Nowadays, 
even though those patients tend to present a worse prognosis, a limb salvage 
procedure is considered an option with similar recurrence rates when compared to 
amputations [49]. Prior studies presented the hypothesis that these patients may 
have a worse outcome due to a hematoma formation at the fracture site, with tumor 
cell dissemination [50]. Although the ideal treatment is controversial, some authors 
recommend stabilization of the fracture, which could be achieved by casting, exter-
nal fixation or limited internal fixation followed by neoadjuvant chemotherapy, 
subsequent definite surgical treatment and adjuvant systemic treatment [51, 52].
Radiotherapy has a role for unresectable tumors or in cases of positive margins 
to help with local control. The Cooperative Osteosarcoma Study Group (COSS) has 
presented promising results for the case of unresectable osteosarcomas of the spine 
and pelvis where the treatment with radiation with a curative intent improved the 
5-year survival from 0 to 29% [53, 54]. Additional studies have shown radiation 
is well tolerated by the patients and can achieve up to 76% local control rates [55]. 
These findings seem to indicate osteosarcomas do have at least a moderate response 
Figure 8. 
Radiographic image depicting a pathological fracture through a distal femur osteosarcoma with displacement 
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to radiotherapy, when in the past it used to be considered a radiotherapy resistant 
tumor. Supplementary indications for radiotherapy include symptom palliation and 
this treatment modality has shown to improve patients’ symptoms such as pain in 
case of unresectable tumors [56].
Current investigation trials are in place to uncover targetable mutations that 
could also have prognostic implications as well studies to assess a potential role for 
immunotherapy in osteosarcoma patients [57]. Specifically, Cabozantinib, a tyro-
sine kinase inhibitor used for thyroid and renal cell cancers, has shown anti-tumor 
activity as well as a good tolerance and is currently under investigation through 
multicentre trials [58].
5. Conclusion
Osteosarcoma, the most common primary bone malignancy in children and 
adolescents, has come a long way since its initial approach where all patients under-
went an amputation prior to the 1970’s. Current systemic treatment options along 
the myriad of reconstruction alternatives, have allowed these patients to benefit 
from better survival rates and improved function and quality of life. Nonetheless, 
the overall survival rates have remained stable for the past 50 years, a disappoint-
ing number when compared to other malignancies’ statistics, suggesting more 
resources and research are needed to continue enhancing the outcomes of patients 
suffering from this cancer.
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